The effect of head coverage on the prevention of hypocalcemia and hypomagnesia.

Phase 3

• Conditions: Jaundice.; Neonatal jaundice, unspecified

• Registration Number: IRCT20181006041252N1
• Lead Sponsor: Sabzevar University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Gestational age 30-35 weeks
Lack of congenital anomaly since birth
Lack of receiving sodium bicarbonate and exchange of blood
Lack of mother's catch to the gestational diabetes and hyperparathyroidism
Lack of using anticonvulsants by mother during pregnancy
Non-interference head covering during phototherapy
Perinatal asphyxia (Apgar score in the minute 5 between 0 to 3, Ph and bicarbonate of the umbilical cord less than 7 and 12 respectively).

Exclusion Criteria

Neonatal sepsis
Perinatal asphyxia
Congenital anomalies since birth
Receiving sodium bicarbonate and exchange blood
Mother's catch to the gestational diabetes and hyperparathyroidism
Mother's use of anticonvulsants during pregnancy
Intrauterine gestational retardation
Interventions cover the head during phototherapy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hypocalcemia: A deficiency and low serum calcium concentration in the blood, usually less than 1.2 mmol / L or 9 mg / dL. Timepoint: At the beginning of the study (before the intervention) and 48 hours after phototherapy. Method of measurement: Flame photometry device.;Hypo-magnesium: A deficiency and low serum concentration of magnesium in the blood, which is usually less than 1.5 mg per cent. Timepoint: At the beginning of the study (before the intervention) and 48 hours after phototherapy. Method of measurement: Flame photometry device.

Secondary Outcome Measures

Name	Time	Method
eonatal Jaundice or Hyperbilirubinemia (i.e., over 2 mg / dL). Timepoint: At the beginning of the study (before the intervention) and 48 hours after phototherapy. Method of measurement: Flame photometry device.